Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta‐Analysis
Pooled result · Live birth rateResult — go to the resultRelative risk 0.81 95% CI 0.67–0.98Authors' conclusion
Cabergoline, when continued during pregnancy, is associated with a lower chance of live birth compared to discontinuation of pregnancy at diagnosis of pregnancy in women with prolactinoma. However, there was no increased risk of incident congenital malformation, preterm birth or low birth weight. The analysis suggests careful consideration of cabergoline use in pregnant women with prolactinoma.
Study context
- Population
- Pregnant patients with prolactinoma
- Participants
- 1,387 pregnancies12 studies
- Comparison
- Cabergoline continued during gestation vs discontinuation at pregnancy diagnosis
- Outcome
- Live birth rate
Methodological detailsPRISMA guidelines, PICO model
- PRISMA guidelines
- PICO model
Pooled result
As reported in the abstract
Relative risk
0.81
95% CI 0.67–0.98
P = 0.03
Cabergoline continuedvs Discontinuation
RR 0.81 (95% CI 0.67–0.98); P = 0.03
Further pooled results
Fetal loss and congenital malformations (all pregnancies)
- Fetal loss
- 16.1%
- Congenital malformations
- 4.7%
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Preterm birth | 1.00 (0.93–1.07) | P = 0.97 | |
| Low birth weight | 1.02 (0.90–1.16) | P = 0.71 | |
| 0.512Relative risk (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| Congenital malformationsNo difference | 0.99 (95% CI 0.93–1.07) | P = 0.88 |
Original publication
Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta‐Analysis. Clin Endocrinol (Oxf). Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →